| Literature DB >> 35458594 |
Natalia Calonghi1, Carla Boga2, Patrizia Nitti3, Dario Telese2, Silvia Bordoni2,4, Giovanna Farruggia1,5, Fioretta Asaro3, Martina Grandi1, Chiara Zalambani1, Gabriele Micheletti2.
Abstract
A series of regioisomers of the hydroxystearic acid (HSA) was prepared, and the effect of the position of the hydroxyl group along the chain on a panel of human cancer cell lines was investigated. Among the various regioisomers, those carrying the hydroxyl at positions 5, 7, and 9 had growth inhibitor activity against various human tumor cell lines, including CaCo-2, HT29, HeLa, MCF7, PC3, and NLF cells. 10-HSA and 11-HSA showed a very weak effect. 8-HSA did not show inhibitory activity in all cell lines. The biological role of 7-HSA and 9-HSA is widely recognized, while little is known about the effects of 5-HSA. Therefore, the biological effects of 5-HSA in HeLa, HT29, MCF7, and NLF cell lines were investigated using the Livecyte's ptychography technology, which allows correlating changes in proliferation, motility, and morphology as a function of treatment at the same time. 5-HSA not only reduces cell proliferation but also induces changes in cell displacement, directionality, and speed. It is important to characterize the biological effects of 5-HSA, this molecule being an important component of fatty acyl esters of hydroxy fatty acids (FAHFA), a class of endogenous mammalian lipids with noticeable anti-diabetic and anti-inflammatory effects.Entities:
Keywords: cancer; hydroxystearic acids; ptychography; quantum phase imaging
Mesh:
Substances:
Year: 2022 PMID: 35458594 PMCID: PMC9029951 DOI: 10.3390/molecules27082396
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Hydroxystearic acids considered in current study.
Scheme 1Synthetic routes to HSA derivatives 5a–e.
Scheme 2Synthesis of 11-HSA (5f).
IC50 (μM) values of the HSA derivatives in the analyzed tumor cell lines.
| 5-HSA | 7-HSA | 8-HSA | 9-HSA | 10-HSA | 11HSA | |
|---|---|---|---|---|---|---|
| CaCo2 | 25.1 μM | 42.5 μM | > 100μM | 32.6 μM | 68.3 μM | 27.6 μM |
| HT29 | 51.3 μM | 14.7 μM | > 100μM | 30.7 μM | 77.2 μM | 56.9 μM |
| HeLa | 22.1 μM | 26.6 μM | > 100μM | 26.9 μM | 41.7 μM | 31.5 μM |
| MCF7 | 46.4 μM | 21.4 μM | > 100μM | 49.1 μM | 38.7 μM | 35.8 μM |
| PC3 | 31.6 μM | 24.3 μM | > 100μM | 23.4 μM | 34.0 μM | 61.4 μM |
| NLF | 38.5 μM | 24.9 μM | > 100μM | 33.1 μM | 74.6 μM | 29.7 μM |
Figure 2Quantitative phase images. Representative images at 0 and 72 h of HeLa, HT29, MCF7, and NLF control cells and treated with 50 μM 5-HSA. Yellow circles indicate dense cells.
Figure 3Effect of 50 μM 5-HSA treatment on cell proliferation and morphology. (A) Histogram plot illustrating median cell doubling time. (B) Distribution of the cellular dry mass for HeLa, MCF7, HT29, and NLF cells, treated and control. (C) Histogram plot illustrating dry mass doubling time of cells, treated and control.
Figure 4Analysis of cellular motility. (A) Average confinement ratio of HeLa, MCF7, HT29, and NLF cells over 72 h after treatment. (B) Directionality and (C) Average instantaneous velocity of HeLa, MCF7, HT29, and NLF cells over 72 h after treatment. Error bars represent the inter-quartile range.